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Abstract
Purpose—Chronic sugar-sweetened beverage (SSB) consumption is associated with obesity and 
type 2 diabetes mellitus (T2DM). Hyperglycaemia contributes to metabolic alterations observed in 
T2DM, such as reduced oxidative capacity and elevated glycolytic and lipogenic enzyme 
expressions in skeletal muscle tissue. We aimed to investigate the metabolic alterations induced by 
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SSB supplementation in healthy individuals and to compare these with the effects of chronic 
hyperglycaemia on primary muscle cell cultures.
Methods—Lightly active, healthy, lean subjects (n = 11) with sporadic soft drink consumption 
underwent a 4-week SSB supplementation (140 ± 15 g/day, ∼2 g glucose/kg body weight/day, 
glucose syrup). Before and after the intervention, body composition, respiratory exchange ratio 
(RER), insulin sensitivity, muscle metabolic gene and protein expression were assessed. Adaptive 
responses to hyperglycaemia (7 days, 15 mM) were tested in primary human myotubes.
Results—SSB supplementation increased fat mass (+1.0 kg, P < 0.05), fasting RER (+0.12, P < 
0.05), fasting glucose (+0.3 mmol/L, P < 0.05) and muscle GAPDH mRNA expressions (+0.94 
AU, P < 0.05). PGC1a mRNA was reduced (−0.20 AU, P < 0.05). Trends were found for insulin 
resistance (+0.16 mU/L, P = 0.09), and MondoA protein levels (+1.58 AU, P = 0.08). Primary 
myotubes showed elevations in GAPDH, ACC, MondoA and TXNIP protein expressions (P < 
0.05).
Conclusion—Four weeks of SSB supplementation in healthy individuals shifted substrate 
metabolism towards carbohydrates, increasing glycolytic and lipogenic gene expression and 
reducing mitochondrial markers. Glucose-sensing protein MondoA might contribute to this shift, 
although further in vivo evidence is needed to corroborate this.
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Introduction
Obesity caused by overnutrition and a sedentary lifestyle are the major risk factors for type 2 
diabetes mellitus (T2DM) [1]. T2DM is characterized by defects in insulin secretion, 
elevated hepatic glucose output and impaired glucose uptake in target tissues, especially 
skeletal muscle [2]. Moreover, the metabolic phenotype of skeletal muscle in T2DM is 
associated with an impaired capacity to increase fat oxidation upon increased fatty acid 
availability and to switch between fat and glucose as the primary fuel [3]. Skeletal muscle 
fibres in insulin resistant and T2DM patients show an elevation in glycolytic and lipogenic 
enzyme expression and a reduction in oxidative capacity [4–6], accompanied by a lower 
mitochondrial volume density [7]. Moreover, these patients show an increase in fast 
glycolytic fibre type IId/x content [8]. Interestingly, these same skeletal muscle fibre 
alterations are already evident in obese non-diabetic subjects [9].
Although the role of lipid metabolites in the impairment of cellular insulin response is well 
established [10], knowledge about the contribution of glucose and associated metabolites to 
the development of an underlying metabolic phenotype of T2DM is still emerging. Several 
studies have shown that high glucose availability, in the form of hyperglycaemia, can 
influence signalling pathways that regulate peripheral glucose uptake and metabolic gene 
expression [11–13]. Under hyperglycaemic conditions, metabolic gene expression is 
consistently shifted towards a lower mitochondrial enzyme expression and elevated 
glycolytic and lipogenic expressions in skeletal muscle cells [11–13].
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Chronic sugar-sweetened beverage (SSB) consumption is highly prevalent in the Western 
diet and has been shown to be highly correlated with the development of obesity and T2DM 
[14–16]. However, more evidence is needed to prove that SSB consumption contributes 
uniquely to obesity [17]. In the long term, periods of high glucose availability, induced by 
repeated glucose-based soft drink consumption, could lead to similar metabolic alterations 
as observed in chronic hyperglycaemia. This could contribute to the development of a 
metabolic phenotype such as the one found in insulin resistance and T2DM.
Glucose sensing in skeletal muscle cells, as part of a mechanism for the maintenance of 
cellular energy homoeostasis, has been demonstrated to be strongly dependent on the 
transcription factor MondoA [12]. MondoA seems to be a master regulator of glycolytic 
genes and indeed it activates the transcription of numerous genes encoding metabolic 
enzymes [18]. Glycolytic gene expression is highly upregulated in response to MondoA 
recruitment from cytoplasm to nuclei, building a complex with the transcription factor max-
like protein x (Mlx), in high glucose conditions [12, 19]. A further target of the 
MondoA:Mlx complex is the thioredoxin-interacting protein (TXNIP). TXNIP impairs 
peripheral glucose uptake stimulating radical oxygen species production. Consequently, 
subjects in pre-diabetic and diabetic states show a rise in TXNIP mRNA transcripts in 
skeletal muscle tissue [11]. Thus, chronic high glucose availability in vitro leads to 
MondoA-mediated metabolic alterations in muscle cells, which seem to correspond to those 
found in pre-diabetic and diabetic state in vivo.
For these reasons, we have designed 2 studies. In study 1, we hypothesized that periods of 
high glucose availability, induced by SSB consumption for 4 weeks, can shift the 
metabolism towards carbohydrates, altering metabolic gene expression in the skeletal 
muscle tissue towards an elevation in glycolytic and lipogenic marker enzyme expression 
glyceraldehyde-3-phosphate dehydrogenase and acetyl-CoA carboxylase (GAPDH and 
ACC) and a reduction in mitochondrial marker peroxisome proliferator–activated receptor-
gamma coactivator 1 α and citrate synthase (PGC1α and CS) expression. Moreover, we 
expected an elevated recruitment of MondoA to nuclei and an elevation of TXNIP 
expression. In study 2, we hypothesized that primary human myotubes exposed to chronic 
hyperglycaemia (15 mM) would show metabolic alterations, such as an increase in 
glycolytic and lipolytic capacity and a decrease in oxidative capacity and confirm the 
elevation of MondoA and of TXNIP expressions found in cell lines [11, 12, 18].
Materials and methods
Ethical approval
The departmental ethics committee (of Bangor University) approved the study designs in 
agreement with the Declaration of Helsinki. All subjects involved in these studies were 
given a participant information sheet and signed an informed consent form, prior to testing.
In vivo study
Subjects and study design—A pre-test–post-test within subject design was used. An 
initial screening for lifestyle and SSB consumption was executed via qualitative 
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questionnaires. Healthy people with low physical activity and consuming less than 500 ml of 
SSB per week were considered eligible to take part in this study (32 out of 213 people 
screened). Eleven subjects, 5 males and 6 females (Table 1), consented to take part in this 
study. The subjects were informed that they would receive £100 upon completion of testing 
as compensation for their time. Before and after the intervention period, subjects attended 
our laboratories for two testing sessions. Although all the subjects included in this study had 
a low physical activity, they were explicitly asked to refrain from exercise for 24 h prior to 
all tests. Post-tests were conducted at least 36 h after the last SSB consumption. One subject 
was not able to attend the post-intervention oral glucose test and the muscle biopsy because 
of a viral infection. Only dietary and body composition data of this subject were used for the 
statistical analysis.
Study intervention—Subjects underwent a 4-week SSB supplementation (Lucozade 
Energy, GlaxoSmithKline plc, Harlow, UK) on top of their habitual diet. The ingredients of 
Lucozade Energy were the following: carbonated water, glucose syrup (24 %), orange juice 
from concentrate (5 %), citric acid, preservatives (sodium benzoate, sodium bisulphate), 
flavourings (including caffeine), stabilizer (acacia gum), antioxidant (ascorbic acid) and 
colour (beta carotene). The SSB was provided by the experimenters. Supplementation was 
carried out on the basis of a daily carbohydrate intake of ≈ 2.0 g/kg body weight. This 
corresponded on average to 760 mL SSB per subject per day. Empty SSB bottles were 
collected.
Diet diaries and body composition—Subjects were introduced to the diet diaries via 
standard instruction [20]. Subjects were asked to keep a 7-day diet diary for a week before 
the intervention started and a 14-day diet diary during the supplementation month [21]. The 
diet analysis was conducted using the United States Department of Agriculture food search 
for windows, Version 1.0, database version SR21 in combination with nutritional 
information labels. Lean mass, fat mass and bone mineral content were assessed by Dual-
energy X-ray Absorptiometry (DXA) (QDR1500, software version 5-72; Hologic, Waltham, 
MA, USA) as described previously [22].
Indirect calorimetry—Subjects were asked to attend this test session in an overnight (8–
12 h) fasted condition. The meal prior to the indirect calorimetry and the blood and muscle 
sampling met the World Health Organization recommendations [23] for an oral glucose 
tolerance test. Respiratory exchange ratio (RER) was measured by indirect calorimetry 
(Meta-Lyzer 3B, Cortex Biophysik, Leipzig, Germany), following da Rocha et al.'s 
recommendations [24]. Ambient temperature of 20 °C and 40 % humidity were kept 
constant throughout this test that was carried out in a climate chamber. The steady state 
coefficient of variation for our indirect calorimetry system was below 5 %. Subjects with a 
coefficient of variation above this value were excluded from the statistical analysis. 
Substrate oxidation rates were calculated based on indirect calorimetry, assuming a constant 
urinary nitrogen excretion (n) equal to 0.01 g/min. The equations used to calculate the 
substrate oxidation rate were:
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where c and f are the grams of carbohydrate and fat oxidized per min, respectively [25].
Blood sample analysis—An overnight fasting venous blood sample (4 mL) was 
collected in heparinized vacutainers from the antecubital vein of each subject. Then, a 75-g 
oral glucose load was administered to the subjects and after 1 h a new venous blood sample 
was drawn. Plasma glucose was analysed for each sample by immobilized enzymatic assay 
(YSI 2300 STAT, Incorporated Life Sciences, Yellow Springs, OH, USA). Lipid profile was 
analysed from the fasting plasma samples by optic enzymatic assay (Reflotron®, Roche 
Diagnostics, Mannheim, Germany). The plasma samples were then stored at -40 °C for later 
plasma insulin analysis. Plasma insulin was analysed by ELISA (Ultrasensitive human 
insulin ELISA-kit, Mercodia, Uppsala, Sweden). Homeostasis model assessment (HOMA) 
calculator, version 2.2.2., was used to compute steady state beta cell function (%B), insulin 
sensitivity (%S) and insulin resistance (IR) (http://www.dtu.ox.ac.uk/homa).
Muscle biopsies—The needle muscle biopsies were taken 1 h after the glucose load. 
After local anaesthesia (1 % lignocaine), 2 needle muscle biopsies were collected at a mid-
distance between the great trochanter and the femorotibial joint on the vastus lateralis (VL) 
muscle of the left leg of the volunteers. Biopsies were taken with a 14-gauge needle (14ga × 
10 cm, Tru•Core® II Biopsy Instrument, Angiotech Gainesville, FL, USA). The biopsies for 
the post-test were taken about 0.5–1 cm from the pre-test biopsies. Muscle specimens were 
snap-frozen and stored in liquid nitrogen until further analysis.
Real-Time PCR—The frozen muscle biopsies (15.6 ± 0.30 mg) were pulverized (1,900 
rpm for 15 s) at liquid nitrogen temperature by using a micro-dismembrator (Sartorius-
Stedim Biothec, Goettingen, Germany). Total RNA was isolated using an RNeasy Fibrous 
Tissue Kit (RNeasy, Qiagen Ltd, Crawley, West Sussex, UK) with DNase treatment 
following the manufacturer's instructions. RNA concentration and purity were measured at 
260 nm and 280 nm. Total RNA concentrations averaged around 108 ± 37 μg/mL. cDNA 
was synthesized from 50 ng RNA using a reverse transcription kit (Sensiscript, Qiagen Ltd, 
Crawley, West Sussex, UK) at 37 °C for 60 min after heating for 5 min at 65 °C. cDNA was 
stored at -80 °C until use.
Real-time RT-PCR was performed using 2× Quantitect SYBR green PCR master mix 
(Qiagen Ltd, Crawley, West Sussex, UK) on a fast real-time PCR system (7900HT, Applied 
Biosystems, Carlsbad, California, USA). Primers for each gene (supplementary Table 1) 
were selected from published sources or designed using reference mRNA sequences 
(National Centre for Biotechnology Information, National Library of Medicine, Bethesda, 
MD, USA) and Primer3 software (http://frodo.wi.mit.edu/primer3/). All primers were 
confirmed for homologous binding to the desired mRNA targets by conducting a BLAST 
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search (http://blast.ncbi.nlm.nih.gov/) once chosen primers were synthesized (Eurofins 
MWG Operon, Ebersberg, Germany). cDNA transcripts of all genes of interest were 
measured simultaneously in duplicates. To normalize the gene expression, 18s rRNA was 
used as an endogenous control. Each reaction contained PCR master mix, forward and 
reverse primers (0.3 μM), RNase free water and 2.5 μL cDNA in 25 μL final volume. 
Thermal cycling conditions were as follows: PCR initial activation step of 15 min at 95 °C, 
3 step cycling of 15 s denaturation at 94 °C, 30 s annealing at 50–60 °C (varied with primer) 
and 30s extension at 72 °C for 45 cycles. The melting curves that were performed after all 
runs showed single products in each case. Critical threshold (CT) values were recorded for 
the target gene and the endogenous control, and these values were used to quantify mRNA 
expression. The standard curve method (User Bulletin 2 ABI PRISM 7700 Sequence 
Detection System) was used to quantify relative amounts of mRNA for each gene. The 
standard curve was made by preparing a series of 10 dilutions of template cDNA for both 
the target gene and the endogenous control; these were run simultaneously with all samples.
Western blotting and myosin heavy chain (MHC) analysis—The frozen muscle 
biopsies and 150 μL of frozen buffer, containing 10 % PBS, 5 % protein phosphatase 
inhibitors, 0.1 % of 1 M DTT, 0.05 % protease inhibitor and 0.1 % detergent (Nuclear 
Extraction Kit, Activemotif, Rixensart, Belgium) were pulverized (1,900 rpm for 15 s) at 
liquid nitrogen temperature by using a micro-dismembrator (Mikro-Dismembrator S, 
Sartorius-Stedim Biotech, Goettingen, Germany). The pulverized muscle samples were 
thawed on ice and centrifuged at 4 °C (20,000×g for 5 min). The supernatants were used to 
assess ACC, fumarate hydratase (FUM), GAPDH and TXNIP expression levels. Pellets, 
containing nuclei and muscle fibrils were extracted on ice by means of an ultrasonic 
processor (VCX 130, Sonics & Materials INC, Newtown, CT, USA), with myosin extraction 
buffer (0.6 M KCl, 1 mM EGTA, 10 mM sodium phosphate dibasic, 1 mM PMSF, pH 6.8) 
at 0 °C. Extracts were centrifuged at 20,000×g for 20 min at 4 °C and crude nuclear 
membrane fraction resuspended in SDS-sample buffer and used to assess MondoA 
expression levels. The protein content of the muscle samples was assessed by Lowry protein 
assay (Sigma-Aldrich, Saint Louis, MO, USA). Equal amounts of total protein per lane were 
separated electrophoretically in 10 or 5 % SDS-PAGE and were then transferred to a 
nitrocellulose membrane (Hybond ECL 6 × 8 cm, GE Healthcare, Amersham, Slough, UK). 
Loading control was performed using India ink staining of the nitrocellulose membranes 
after blotting and normalization was carried out based on α-actin signal levels. After 
blocking in PBS, containing 0.2 % Tween and 5 % low-fat dry milk, blots were probed with 
primary antibodies for 4 h at dilutions of 1:250, 1:2,000 and 1:10,000 for ACC (H-76) 
(sc-30212), FUM (J-13) (sc-100743) and GAPDH (0411) (sc-47724), respectively (Santa 
Cruz Biotechnology Inc, Santa Cruz, CA, USA). MondoA (1:500) [18] and TXNIP 
(1:1,000) (MBL, Naka-ku Nagoya, Japan) were incubated overnight. As secondary 
antibodies, goat anti-rabbit IgG-HRP 1:15,000 (Sigma-Aldrich, St. Louis, MO, USA) or 
goat anti-mouse IgG-HRP 1:5,000 (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA) 
were used. ECL (Amersham Hyperfilm ECL, 18 × 24 cm, GE Healthcare Life Sciences, 
Little Chalfont, UK) detection was carried out using the SuperSignal West Pico or Femto 
ECL kit (Pierce, Rockford, IL, USA). If necessary, membranes were stripped for 45 min at 
50 °C in stripping buffer (10 % SDS, 0.5 M Tris, pH 6.8 and 0.08 % β-mercaptoethanol), 
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washed for 1 h and re-probed. Densitometry was then used to quantify protein bands (Gel 
Doc 2000 and software Quantity One-4.6.3, Bio-Rad, Hercules, CA, USA). MHC extraction 
and electrophoresis were executed as described in Sartor et al. [22].
In vitro study
Primary cell cultures—Four muscle biopsies were taken from healthy male subjects 
(age, 38 ± 13 years; height, 1.79 ± 0.06; weight, 72 ± 6 kg) for the isolation of satellite cells. 
After muscle biopsies were taken, tissue was immediately transferred to RT skeletal muscle 
growth medium (SMGM) with 5 % foetal calf serum (FCS), 1 % L-glutamine with penicillin/
streptomycin plus supplements (PromoCell, Heidelberg, Germany), and washed in medium 
twice. This was followed by disintegration with surgical blades with 0.05 % trypsin (PAA, 
Pasching, Austria) in PBS for 30 min, after which trypsination was stopped by trypsin 
inhibitor (Sigma-Aldrich, St. Louis, MO, USA) with a final concentration of 0.14 mg/mL. 
After centrifugation at 800×g for 5 min at 10 °C, the pellet was resuspended in accutase 
(PAA, Pasching, Austria) and additionally incubated for 20 min at 37 °C. After 
sedimentation, the cell suspension was centrifuged again at 800×g for 5 min at 10 °C, and 
the cell pellet was resuspended in SMGM with 5 % FCS, 1 % L-glutamine with penicillin/
streptomycin plus supplements (PromoCell, Heidelberg, Germany). The cell suspension was 
transferred into 75-cm2 TC flasks (Greiner, Frickenhausen, Germany) and incubated at 37 
°C, 5 % CO2 and 95 % humidity until passage. Half-medium change was performed every 
second day. Three passages were completed before the initiation of differentiation 
(Supplementary Fig. 1). The samples of the human primary myotubes were tested for 
creatine kinase activity after the initiation of differentiation in DMEM (PAA, Pasching, 
Austria) with 2 % FCS for 4 days.
For the cultivation of the differentiated myocytes, grown on microcarriers, 5 × 106 cells per 
10 mL medium were seeded on microcarriers in suspension (0.015 g microcarriers, 
CultiSpher-GL; Percell Biolytica, Astorp, Sweden) in 25-cm2 flasks. Flasks were placed on 
a circular shaker (53 rpm) to guarantee adequate O2 supply to the cells and to prevent the 
cells and microcarriers from settling down. After 12 days of differentiation in DMEM with 2 
% FCS, myotubes were exposed to high glucose, DMEM with 2 % FCS, 15 mM D-glucose 
(Sigma-Aldrich, St. Louis, MO, USA) and 10 μg/mL of insulin (Actrapid, Novo Nordisk 
A/S, Bagsvaerd, Denmark). Control myotubes were cultivated in DMEM with 2 % FCS, 5 
mM D-glucose and 10 μg/mL insulin. Exposure time to high glucose or control conditions 
was 7 days.
Cell harvest and Western blotting—The myotubes on microcarriers were washed with 
PBS, lysed and denatured with SDS-PAGE sample buffer at 95 °C for 3 min and cooled on 
ice. The samples were cleared by centrifugation at 16,000×g in QIAshredder columns 
(Qiagen, Hilden, Germany). The eluates were frozen in liquid nitrogen and kept at −80 °C 
until use. Nuclear and cytoplasmic fractions from myotubes grown on microcarriers for 12 
days followed by exposure to high glucose (15 mM) and control conditions (5 mM) in 
DMEM with 2 % FCS, 10 μg/mL insulin for 7 days were prepared according to the 
manufacturer's protocols using a nuclear extraction kit (Kit No400010&No40410, Active-
motif, Rixensart, Belgium).
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Statistics
The statistical analysis was performed using SPSS 11.5. Unless otherwise specified, all data 
are reported as means ± SDs. Outcomes of the in vivo study were analysed with Student's 
paired samples t-tests. The in vitro outcomes were analysed with non-parametric Mann-
Whitney U tests. Pearson correlations for the differences between pre- and post-tests were 
conducted. The significance level was set at 0.05 (two-tailed). The level for trends was set at 
0.10.
Results
In vivo study
Resting glucose levels, insulin sensitivity and metabolic substrate preference
—The SSB supplementation significantly increased fasting plasma glucose levels, while 
fasting plasma insulin levels showed a clear trend towards an elevation (pre, 4.83 ± 0.43 
mmol/L, post, 5.13 ± 0.38 mmol/L, P < 0.05; pre, 4.95 ± 1.90 mU/L, post, 6.40 ± 1.62 
mU/L, P = 0.09, respectively) (Fig. 1a and b). Moreover, HOMA 2 revealed that %S was 
diminished, and IR was increased (Table 1). %B showed no response. Blood lipids (Table 1) 
did not change after the 4-week intervention. The analysis of resting substrate metabolism 
after overnight fasting, measured by indirect calorimetry, revealed a significant increase in 
RER (pre, 0.75 ± 0.09, post, 0.87 ± 0.08; P < 0.05, n = 8) (Fig. 1d). Calculation of the 
preferred substrate oxidation demonstrated that metabolism changed from the expected high 
level of fat oxidation to a strong preference for carbohydrate oxidation after only 4 weeks 
intervention (Fig. 1c).
Diet diary analysis and body composition—The analysis of daily macronutrient 
intake (Table 2) shows that the energy intake during the SSB supplementation was not 
significantly different from the energy intake at baseline. Moreover, carbohydrate and 
especially sugar intake were strongly increased during the intervention, with a concomitant 
reduction in protein intake and PUFA (Table 2). The body composition analysis by DXA 
revealed a significant increase in fat mass while lean mass did not change (Table 1).
Myosin heavy chains and metabolic gene/protein expression in skeletal 
muscle—MHC electrophoresis and quantification showed no difference in fibre type 
composition between pre- and post-intervention, confirming that results were not 
confounded by variability in the origin of the muscle biopsies (Table 3). Post-
supplementation metabolic gene expressions in the VL muscle were altered. The gene 
expression of the glycolytic marker GAPDH increased significantly, and the gene 
expression of the lipogenic marker ACC revealed a trend towards an increase (P < 0.05, P = 
0.09, respectively), while the gene expression of the co-transcription factor PGC1α used as a 
marker for mitochondrial gene expression was significantly reduced (P < 0.05). No 
alteration in the expression of CS mRNA was detected (Table 3). Western blot analysis of 
metabolic markers (GAPDH, ACC, FUM) on protein levels showed no significant 
alterations (pre, 1.00 ± 0.24 AU, post, 0.93 ± 0.37 AU, P = 0.393; pre, 1.00 ± 0.55 AU, post, 
0.84 ± 0.47 AU, P = 0.328; pre, 1.00 ± 0.35 AU, post, 0.79 ± 0.41 AU, P = 0.179, 
respectively).
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MondoA expression in skeletal muscle biopsies—Western blot analysis of 
MondoA content in the crude nuclei membrane fraction of biopsy samples showed a strong 
trend towards an elevated protein content of this transcription factor (pre, 1.00 ± 1.08 AU; 
post, 2.58 ± 2.46 AU; P = 0.08) (Fig. 2a and b). However, TXNIP protein expression did not 
change significantly (pre, 1.00 ± 0.38 AU; post, 1.24 ± 0.49 AU; P = 0.21) (Fig. 2c and d). 
Changes in TXNIP expression correlated significantly with changes in MondoA expression 
(r = 0.88, P < 0.01, n = 10) (Fig. 2e). In line with the results for MondoA on protein level, 
RT-PCR analysis revealed a strong trend towards an elevated MondoA mRNA transcription 
after the SSB supplementation (P = 0.057).
In vitro study
MondoA and TXNIP protein expressions in human primary myotubes—Western 
blot analysis of cell homogenates revealed that expression levels of MondoA and TXNIP 
were increased after 7 days of high glucose availability (190 ± 30 % and 352 ± 47 % of 
control; P < 0.05) (Fig. 3a and b). The expression of TXNIP was highly correlated with the 
expression of MondoA (r = 0.87; P < 0.011; n = 7) (Fig. 3c). Additionally, nuclear and 
cytoplasmic fractions derived from the cultured myocytes showed that MondoA is strongly 
recruited to the nuclei membrane fraction under hyperglycaemic conditions (Fig. 3a).
Glycolytic and lipogenic enzymes—Western blot analysis of glycolytic, oxidative and 
lipogenic marker enzymes from myotubes exposed to hyperglycaemia for 7 days showed a 
significant increase in glycolytic GAPDH and lipogenic ACC expressions compared with 
controls (173 ± 32 % and 177 ± 18 % of control; P < 0.05). The oxidative marker enzyme 
FUM did not respond to the high glucose exposure (91 ± 30 % of control; P = 0.44) (Fig. 4).
Discussion
The major finding of this work is that 4 weeks of periodic high glucose availability can 
induce metabolic alterations in skeletal muscle in vivo comparable to adaptations of muscle 
cells towards chronic hyperglycaemic conditions in vitro. Because of the limited duration of 
the SSB supplementation, for evident ethical reasons and its periodic nature, 2 drinks per 
day, in vivo skeletal muscle metabolic changes were visible mainly at mRNA level. 
However, a clear metabolic shift towards carbohydrates was detectible at a protein level in 
vitro.
In detail, we observed that 4 weeks of SSB supplementation led to a significant increase in 
fasting plasma glucose and a strong trend towards a reduction in insulin sensitivity in 
healthy lean individuals with low physical activity, who otherwise consumed less than 500 
mL SSB per week. This selection was necessary to avoid any pre-existing physiological 
adaptation to soft drink consumption. These outcomes are in line with previous 
investigations in healthy as well as hyperinsulinemic subjects [26, 27]. The SSB 
supplementation elicited adipose tissue deposition, and this may have contributed to the 
alterations found in the insulin system and in the metabolism of the skeletal muscle cells. 
However, it has been shown that changes in insulin sensitivity can be independent of 
changes in fat mass [28]. Additionally, in our human myotubes metabolic changes were 
found in the absence of extracellular adipose tissue activity. Several studies have shown that 
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neither high-glycemic-index food intake nor glucose intake just before bedtime increases 
overnight fasting blood glucose and insulin levels [29–31]. Therefore, the alterations that we 
have detected should be related to long-lasting adaptations in glucose homoeostasis and 
metabolism, produced by the 4 weeks of SSB supplementation. It is highly unlikely that our 
outcome could be explained merely by an acute effect of the last soft drink intake, which 
occurred not less than 36 h before the post-intervention blood tests.
Certainly, limited glycogen storage capacity may contribute to these adaptational responses, 
and it is plausible that after 4 weeks of periodic high glucose load, glycogen storage capacity 
gradually reached its maximum, increasing the need for enhanced glycolysis, glucose 
oxidation and lipogenesis to reduce intracellular glucose availability [32]. This interpretation 
is supported by the increase in overnight-fasted resting RER, which represents a ∼40 % 
reduction in lipid oxidation and concomitant increase in carbohydrate oxidation. The high-
carbohydrate-induced RER increase is in line with previous investigations [33]. Lipid 
oxidation is known to be inhibited following carbohydrate ingestion during exercise [34, 
35], and it has also been shown to be reduced in post-prandial periods [36]. Work on rodents 
has shown that fat oxidation is reduced after a high-glycemic-index diet as early as 3 weeks 
after onset of the diet preceding the development of obesity [37], and more recently, Roberts 
and colleagues [38] have shown that a 3-day sugar-rich diet leads to a reduced post-prandial 
fat oxidation in non-obese subjects, even without a change in fasting RER.
Alterations towards higher glycolytic and lipogenic capacity in skeletal muscle cells are 
typical of the metabolic phenotype seen in T2DM [39]. Glycolytic and lipogenic enzymes 
have been shown to possess carbohydrate response elements (ChoRE) in their promoter 
sequences [40, 41]. Indeed, we found that after 4 weeks of SSB consumption, skeletal 
muscle metabolic gene expressions were altered towards a higher expression of glycolytic 
enzyme (GAPDH), a known target gene of MondoA in skeletal muscle, a tendency towards 
a higher lipogenic (ACC) gene expression and a reduced gene expression of mitochondrial 
co-transcription factor PGC1α, a master regulator of mitochondrial transcription [42]. 
However, CS mRNA expression was not altered; this could possibly due to the level of 
physical activity of our subjects leading to calcium transients and calcium-dependent signal 
transduction in skeletal muscle [43]. It has been shown recently that calcium-dependent 
activation of CS transcription can suppress the negative influence of glucose signalling on 
CS expression in muscle cell culture experiments [13]. Otherwise, this does not exclude 
strong effects of sugar consumption on mitochondrial gene expression in sedentary people 
and after longer exposure times. An elevated ratio of glycolytic to mitochondrial enzymes 
has been shown in insulin-resistant and T2DM muscle [6], and reduced mitochondrial 
transcription has also been shown to be dependent on glycogen levels [44, 45]. Moreover, a 
similar adaptational response, as shown by elevations of GAPDH and ACC on protein level, 
was found in our in vitro study, during which primary muscle cell cultures were exposed to 
hyperglycaemia for 1 week. These findings are in line with the results seen in primary 
muscle cell cultures from rabbit and from a C2C12 cell line under hyperglycaemic 
conditions [13] and hypoglycaemic conditions [44].
While hyperglycaemia in T2DM may be the result of processes related to impaired beta cell 
function [46], adipokine signalling [47] or influence of lipid metabolites [10], the 
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contribution of glucose-dependent signalling for the development of the metabolic 
phenotype found in skeletal muscle in T2DM seems a highly plausible explanation too. The 
development of this metabolic phenotype could be enhanced by glucose-sensing 
transcription factors such as MondoA. To our knowledge, this was the first attempt to study 
MondoA responses in vivo. SSB consumption for 4 weeks led to a trend towards an 
increased protein expression of MondoA and to a significant correlation between changes in 
MondoA and changes in TXNIP protein expressions in skeletal muscle in vivo. Our in vitro 
work with human skeletal muscle cell cultures, which we exposed to hyperglycaemia for 7 
days, showed a stronger response and correlation, suggesting a key role for MondoA in 
glucose-induced metabolic adaptations. In fact, in vitro MondoA and TXNIP were 
upregulated, and MondoA was found predominantly in the nuclear fraction. This is in 
accordance with the findings of Stoltzman and colleagues [12] in L6 cells. MondoA has 
been shown to contribute to 75 % of glucose-induced gene expression in HA1ER cells using 
Agilent 44 K human microarrays [12], and MondoA is certainly both necessary and 
sufficient for glycolytic enzyme expression, as demonstrated in C2C12 and K562 cells [18]. 
However, the influence of intramuscular lipids cannot be excluded. MondoA has also been 
recognized as the transcription factor that upregulates the expression of TXNIP [12]. TXNIP 
is involved in peripheral glucose uptake inhibition, especially in skeletal muscle [11] and it 
is a critical regulator in glucose production in the liver [48]. Moreover, TXNIP has been 
shown to be increasingly transcribed in skeletal muscle of pre-diabetics and T2DM patients, 
and it has been suggested that it contributes to the development of T2DM [11, 49]. The lack 
of a clear TXNIP response in our in vivo study might be explained by the limited duration of 
the periodic high glucose availability, but also by the increase in circulating insulin induced 
by the SSB supplementation in healthy individuals. In fact, Kaadige and colleagues [50] 
have shown that in the presence of glutamine, high glucose availability still activates 
MondoA, thereby inhibiting TXNIP, and insulin is known to stimulate glutamine transport 
into the muscles [51]. This was observed also in human adipocytes [11]. In addition, the 
more marked cellular adaptations (i.e. MondoA and ACC) observed in vitro compared with 
those detected in vivo are likely also due to the higher and chronic glucose exposure. In our 
in vitro study, we have used 15 mmol/L (270 mg/dL) of glucose, a concentration observable 
in post-prandial T2DM patients [52, 53]. Conversely, in our in vivo study, healthy subjects 
were exposed to circa 65 g of glucose twice a day causing two blood glucose peaks of 
around 7–8 mmol/L. Importantly, the amount of SSB that we have used in our study does 
not differ much (760 mL) from the mean value of soft drink consumption per capita per day 
in the United Kingdom (∼650 mL) in 2010 [54]. In real life, SSB users are often exposed to 
similar sugar levels for years; making our in vitro results a good indication of what might 
occur in the long run. However, care must be taken when drawing conclusions; in fact, in 
this study we used a commercially available, glucose syrup-based SSB, but more and more 
frequently, even in Europe, SSBs are made with high fructose corn syrups (glucose and 
fructose); thus, the role of fructose on metabolism, next to the one played by glucose 
investigated here, should not be underestimated.
It has been shown that SSBs play an important role in the aetiology of obesity and that they 
may increase the risk of T2DM [14–16]. The results presented in present article, on the 
metabolic effects of SSBs, along with the effects of SSBs on taste perception [21] add 
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experimental evidence in favour of an important role played by SSBs in the development of 
obesity and T2DM. The alterations that we have found as a result of the SSB 
supplementation do not only include metabolic responses based on the altered substrate 
availability, but also transcriptional responses that could lead to chronic alterations in 
metabolism. The reasons why periods of high glucose availability can achieve similar 
metabolic responses to chronic hyperglycaemia might be found on various levels. However, 
we suggest that carbohydrate dependent signalling systems such as MondoA in muscle, and 
possibly MondoB in liver, might contribute to our findings. Further evidence, such as larger 
and if possible longer trials, is needed to consolidate and clarify the role of MondoA in the 
metabolic shift caused by SSB consumption. In conclusion, 4 weeks of SSB 
supplementation shifted substrate metabolism towards carbohydrates, increasing glycolytic 
and lipogenic gene expression in muscle.
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Fig. 1. 
Fasting plasma glucose, insulin, substrate utilization and respiratory exchange ratio (RER). a 
Overnight fasting plasma glucose levels and b Fasting plasma insulin levels before and after 
4 weeks of sugar-sweetened beverage (SSB) supplementation. c Substrate oxidation rate 
derived from the RER, measured after overnight fast before and after 4 weeks of SSB 
supplementation. d RER (VCO2/VO2) measured by indirect calorimetry after overnight fast 
before and after the intervention. Data are presented as means ± SEMs. *P < 0.05 and #P < 
0.10 for differences between pre- and post-intervention (a and b, n = 10; c and d, n = 8)
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Fig. 2. 
MondoA and thioredoxin-interacting protein (TXNIP) expression. a Western blot analysis of 
MondoA in nuclear membrane fraction from skeletal muscle biopsies before and after 4 
weeks of sugar-sweetened beverage (SSB) supplementation, with α-actin as loading control. 
Image insert shows an example of MondoA Western blots of strong responders to the SSB 
consumption. b Densitometric quantification of Western blots for MondoA, pre- and post-
intervention. c Western blot analysis of TXNIP in cytoplasmic fraction of skeletal muscle 
biopsies pre- and post-intervention. d Densitometric quantification of Western blots for 
TXNIP, pre- and post-intervention. e Correlation between changes in MondoA and changes 
in TXNIP expression (r = 0.88, P < 0.01, n = 10). Data are presented as means ± SEMs. #P 
< 0.10 for differences between pre- and post-intervention (n = 10)
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Fig. 3. 
MondoA and thioredoxin-interacting protein (TXNIP) expression in vitro. a Western blot 
analysis of MondoA and TXNIP expression in primary muscle cell culture under conditions 
of hyperglycaemia (15 mM) and control (5 mM)—12 days plus 7 days exposure, with α-
actin as loading control. MondoA cytoplasmic and nuclear fractions were derived from the 
same cultures. b Densitometric quantification of Western blots for MondoA and TXNIP, 
expressed as a percentage of control. c Pearson correlation between MondoA and TXNIP. 
Open dots represent myotube cultures exposed to normal glucose (5 mM); closed dots 
represent myotube cultures exposed to high glucose (15 mM) (r = 0.87; P < 0.01; n = 7). 
Data are presented as means ± SEMs, *P < 0.05 for differences between glucose conditions
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Fig. 4. 
Metabolic marker enzyme expressions in vitro. a Western blot analysis of metabolic markers 
acetyl CoA Carboxylase (ACC), fumarate hydratase (FUM) and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) in primary muscle cell culture (after 12 days 
cultivation) exposed to hyperglycaemia (15 mM) and control (5 mM) for a further 7 days. b 
Densitometric quantification of Western blots for ACC, FUM and GAPDH, expressed as a 
percentage of control. Data are presented as means ± SEMs. *P < 0.05 for differences 
between glucose conditions (n = 7)
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Table 1
Subject characteristics pre- and post-intervention
Parameters (units) (n) Baseline Post-intervention P level
Age (yrs) (11) 26 ± 7
Height (m) (11) 1.74 ± 0.09
Weight (kg) (11) 65.9 ± 10 66.8 ± 11 0.13
BMI (kg/m2) (11) 21.6 ± 1.5 22.0 ± 1.8 0.09#
Body composition
 Fat mass (kg) (11) 15.2 ± 5.1 16.2 ± 4.7 0.03*
 Lean mass (kg) (11) 48.1 ± 12.6 48.0 ± 13.0 0.90
HOMA 2
 %B (%) (10) 76.6 ± 28.4 81.3 ± 21.8 0.57
 %S (%) (10) 158 ± 47 126 ± 32 0.06#
 IR (10) 0.68 ± 0.19 0.84 ± 0.20 0.08#
Blood lipids
 Total cholesterol (mmol/L) (10) 4.27 ± 0.89 4.42 ± 0.73 0.31
 Triglycerides (mmol/L) (10) 1.01 ± 0.36 1.02 ± 0.33 0.88
 HDL (mmol/L) (10) 1.30 ± 0.21 1.29 ± 0.22 0.86
 LDL (mmol/L) (10) 2.52 ± 0.75 2.67 ± 0.64 0.38
HOMA homoeostasis model assessment, %B steady state beta cell function, %S insulin sensitivity, IR insulin resistance
*
P < 0.05,
#
P < 0.10
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Table 2
Diet diary analysis of macronutrient and energy intake
Parameters (units) (n = 11) Baseline Post-intervention P level
Energy (kcal/d) 2,383 ± 654 2,463 ± 538 0.68
Protein (g/d) 83.4 ± 21.1 71.0 ± 23.2 0.008**
Carbohydrate (g/d) 264 ± 72 347 ± 65 0.005**
Sugar (g/d) 98.6 ± 40.2 183.9 ± 32.1 <0.001***
Total Fat (g/d) 93.1 ± 33.5 72.5 ± 34.8 0.05*
MUFA (g/d) 40.6 ± 15.7 33.3 ± 17.6 0.12
PUFA (g/d) 10.7 ± 5.1 7.4 ± 4.6 0.04*
SFA (g/d) 41.8 ± 19.0 31.7 ± 16.9 0.08#
Dietary fibre (g/d) 19.6 ± 5.9 18.5 ± 5.8 0.29
Protein (%) 14.3 11.8
Carbohydrate (%) 45.5 57.8
Total Fat (%) 36.3 27.4
MUFA monounsaturated fat, PUFA polyunsaturated fat, SFA saturated fat
#
P < 0.10,
*
P < 0.05,
**
P < 0.01 and
***
P < 0.001
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Table 3
Myosin heavy chain composition and gene expression
Parameters (n = 10) Baseline Post-intervention P level
MHC I (%) 52.2 ± 17.0 50.4 ± 15.5 0.66
MHC IIa (%) 45.4 ± 19.3 46.8 ± 17.6 0.73
MHC IIx (%) 2.4 ± 7.6 2.8 ± 8.9 0.34
GAPDH mRNA (AU) 1.00 ± 0.74 1.94 ± 1.52 0.03*
ACC mRNA (AU) 0.99 ± 0.52 1.21 ± 0.78 0.09#
PGC1 α mRNA (AU) 0.96 ± 0.44 0.79 ± 0.53 0.04*
CS mRNA (AU) 1.00 ± 0.38 0.98 ± 0.66 0.94
MondoA mRNA (AU) 0.36 ± 0.25 0.44 ± 0.34 0.06#
MHC myosin heavy chain, GAPDH glyceraldehyde-3-phosphate dehydrogenase, ACC acetyl-CoA carboxylase α, PCG1α peroxisome proliferator-
activated receptor-gamma coactivator 1 α, CS citrate synthase
#
P < 0.10,
*
P < 0.05
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